Literature DB >> 7235023

Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres.

M Chojkier, R J Groszmann.   

Abstract

A method for determining the extent of portal-systemic shunting (PSS) is described and evaluated in lightly anesthetized (ketamine) rats. This method relies on the intrasplenic injection of 15-micrometers gamma-labeled spheres and the subsequent measurement of liver and lung radioactivities. After the splenic injection of the microspheres, a fraction of microspheres shunting the hepatic sinusoidal bed will be entrapped in the lungs. Thus, the ratio, lung/(lung + liver) radioactivities, will indicate the degree of PSS. The percent of PSS was determined in normal (n = 13; 1.2 +/- 0.3%), in cirrhotic (n = 9; 15.0 +/- 4.5%; P less than 0.01), and in portal vein-ligated animals (n = 14; 95.0 +/- 0.9%; P less than 0.001 for normal and cirrhotic). In addition, PSS was sequentially quantitated (n = 3) before (3.0%) and after (89%) partial portal vein ligation. The variability of PSS found in cirrhotic rats (0.7-41.0%) is in agreement with the reported data for PSS in patients. This technique, which is simple, rapid, and reproducible, allows the quantitation of PSS in small laboratory animals.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7235023     DOI: 10.1152/ajpgi.1981.240.5.G371

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  62 in total

1.  Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice.

Authors:  G P Lahvis; S L Lindell; R S Thomas; R S McCuskey; C Murphy; E Glover; M Bentz; J Southard; C A Bradfield
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

2.  The use of quantitative scintigraphy in the measurement of portal-systemic shunting in rats.

Authors:  R E Stauber; T Mochizuki; D H Van Thiel; W N Tauxe
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

3.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

Review 4.  Pathophysiology and epidemiology of portal hypertension.

Authors:  H Okumura; T Aramaki; Y Katsuta
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 5.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

6.  Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis.

Authors:  Nary Veal; Frédéric Moal; Frédéric Oberti; Eric Vuillemin; Paul Calés
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

7.  Hemodynamic studies in a parabiotic model of portal hypertension.

Authors:  E Sikuler; R J Groszmann
Journal:  Experientia       Date:  1985-10-15

8.  Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression.

Authors:  K S Lee; M Buck; K Houglum; M Chojkier
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress.

Authors:  T J Johnson; E M Quigley; T E Adrian; G Jin; L F Rikkers
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

10.  Prehepatic portal hypertension in rats modifies norepinephrine metabolism in hypothalamus, medulla oblongata and portal vein.

Authors:  A Lemberg; F X Eizayaga; M Vatta; A Dominguez; S Romay; L G Bianciotti; G Sansó; B Fernández
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.